Comparison of antivascular endothelial growth factor treatment for myopia choroidal neovascularisation: a systematic review and meta-analysis of randomised controlled trials
暂无分享,去创建一个
[1] B. Karasu,et al. The efficacy of different anti-vascular endothelial growth factor agents and prognostic biomarkers in monitoring of the treatment for myopic choroidal neovascularization , 2022, International Ophthalmology.
[2] T. Lai,et al. Safety review of anti-VEGF therapy in patients with myopic choroidal neovascularization , 2021, Expert opinion on drug safety.
[3] L. Di Antonio,et al. Anti-VEGF Therapy in Myopic CNV. , 2021, Current Drug Targets.
[4] T. Soomro,et al. Three-year real-world outcomes of intravitreal anti-VEGF therapies in patients affected by myopic choroidal neovascularization , 2020, European journal of ophthalmology.
[5] T. Lai,et al. Ranibizumab for myopic choroidal neovascularization , 2020, Expert opinion on biological therapy.
[6] E. Mayo-Wilson,et al. PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews , 2020, BMJ.
[7] Xiaodong Sun,et al. Progression and new onset of macular retinoschisis in myopic choroidal neovascularization eyes after Conbercept therapy: a post-hoc analysis , 2019, Eye.
[8] Haoyu Li,et al. Comparison of intravitreal bevacizumab and ranibizumab used for myopic choroidal neovascularization , 2019, Medicine.
[9] J. Jonas,et al. IMI – Defining and Classifying Myopia: A Proposed Set of Standards for Clinical and Epidemiologic Studies , 2019, Investigative ophthalmology & visual science.
[10] C. Jin,et al. Two different initial treatment regimens of ranibizumab in myopic choroidal neovascularization: 12‐month results from a randomized controlled study , 2018, Clinical & experimental ophthalmology.
[11] You-xin Chen,et al. RANIBIZUMAB VERSUS VERTEPORFIN PHOTODYNAMIC THERAPY IN ASIAN PATIENTS WITH MYOPIC CHOROIDAL NEOVASCULARIZATION , 2018, Retina.
[12] P. Mitchell,et al. Myopic Choroidal Neovascularization: Review, Guidance, and Consensus Statement on Management. , 2017, Ophthalmology.
[13] Y. Ikuno,et al. Diagnosis and treatment guideline for myopic choroidal neovascularization due to pathologic myopia , 2017, Progress in Retinal and Eye Research.
[14] M. Varano,et al. FACTORS INFLUENCING VISUAL ACUITY IN PATIENTS RECEIVING ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR FOR MYOPIC CHOROIDAL NEOVASCULARIZATION , 2017, Retina.
[15] T. Lai,et al. LONG-TERM OUTCOMES OF RANIBIZUMAB TREATMENT OF MYOPIC CHOROIDAL NEOVASCULARIZATION IN EAST-ASIAN PATIENTS FROM THE RADIANCE STUDY , 2017, Retina.
[16] C. S. Lee,et al. CHOROIDAL THICKNESS AND CHORIORETINAL ATROPHY IN MYOPIC CHOROIDAL NEOVASCULARIZATION WITH ANTI–VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY , 2017, Retina.
[17] C. Costagliola,et al. Reduced-fluence verteporfin photodynamic therapy plus ranibizumab for choroidal neovascularization in pathologic myopia , 2017, Graefe's Archive for Clinical and Experimental Ophthalmology.
[18] Ting Zhang,et al. Anti-vascular endothelial growth factor for choroidal neovascularisation in people with pathological myopia. , 2016, The Cochrane database of systematic reviews.
[19] D. Ng,et al. FACTORS INFLUENCING NEED FOR RETREATMENT AND LONG-TERM VISUAL OUTCOME AFTER INTRAVITREAL BEVACIZUMAB FOR MYOPIC CHOROIDAL NEOVASCULARIZATION , 2015, Retina.
[20] T. Wong,et al. Intravitreal Aflibercept Injection in Patients with Myopic Choroidal Neovascularization: The MYRROR Study. , 2015, Ophthalmology.
[21] T. Wong,et al. Myopic choroidal neovascularisation: current concepts and update on clinical management , 2014, British Journal of Ophthalmology.
[22] S. Saviano,et al. Combined therapy with bevacizumab and photodynamic therapy for myopic choroidal neovascularization: A one-year follow-up controlled study. , 2014, International journal of ophthalmology.
[23] S. Kara,et al. Macular hole after intravitreal bevacizumab injection for choroidal neovascularisation , 2014, Clinical and experimental optometry.
[24] T. Wong,et al. RADIANCE: a randomized controlled study of ranibizumab in patients with choroidal neovascularization secondary to pathologic myopia. , 2014, Ophthalmology.
[25] S. Sivaprasad,et al. Ranibizumab in myopic choroidal neovascularization: the 12-month results from the REPAIR study. , 2013, Ophthalmology.
[26] J. Ruiz-Moreno,et al. Intravitreal bevacizumab in myopic neovascular membranes: 24-month results. , 2013, Ophthalmology.
[27] You-xin Chen,et al. INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR FOR CHOROIDAL NEOVASCULARIZATION SECONDARY TO PATHOLOGIC MYOPIA: Systematic Review and Meta-Analysis , 2013, Retina.
[28] M. C. Donati,et al. LONG-TERM RESULTS OF PHOTODYNAMIC THERAPY FOR SUBFOVEAL CHOROIDAL NEOVASCULARIZATION WITH PATHOLOGIC MYOPIA , 2012, Retina.
[29] J. Sterne,et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials , 2011, BMJ : British Medical Journal.
[30] B. Kirchhof,et al. Subjective and functional deterioration in recurrences of neovascular AMD are often preceded by morphologic changes in optic coherence tomography , 2011, British Journal of Ophthalmology.
[31] P. Rosenfeld,et al. NOVEL METHOD FOR ANALYZING SNELLEN VISUAL ACUITY MEASUREMENTS , 2010, Retina.
[32] A. Papayannis,et al. Laser photocoagulation, photodynamic therapy, and intravitreal bevacizumab for the treatment of juxtafoveal choroidal neovascularization secondary to pathologic myopia. , 2010, Archives of ophthalmology.
[33] Eberhard Spoerl,et al. BIOMECHANICAL SIGNIFICANCE OF THE HUMAN INTERNAL LIMITING LAMINA , 2006, Retina.
[34] G. Virgili,et al. Laser photocoagulation for choroidal neovascularisation in pathologic myopia. , 2005, The Cochrane database of systematic reviews.
[35] J. Holladay,et al. Visual acuity measurements. , 2004, Journal of cataract and refractive surgery.
[36] D. Altman,et al. Measuring inconsistency in meta-analyses , 2003, BMJ : British Medical Journal.
[37] M. Mochizuki,et al. Myopic choroidal neovascularization: a 10-year follow-up. , 2003, Ophthalmology.
[38] Jennifer I. Lim,et al. Verteporfin therapy of subfoveal choroidal neovascularization in pathologic myopia: 2-year results of a randomized clinical trial--VIP report no. 3. , 2003, Ophthalmology.
[39] Matthew A. Thomas,et al. Subretinal surgery for choroidal neovascularization in patients with high myopia. , 2000, Archives of ophthalmology.
[40] Rishi P. Singh,et al. A Multinational Comparison of Anti-Vascular Endothelial Growth Factor Use: The United States, the United Kingdom, and Asia-Pacific. , 2019, Ophthalmology. Retina.
[41] Paul Mitchell,et al. Epidemiology and disease burden of pathologic myopia and myopic choroidal neovascularization: an evidence-based systematic review. , 2014, American journal of ophthalmology.
[42] M. Mochizuki,et al. Long-term results of photodynamic therapy for choroidal neovascularization in Japanese patients with pathologic myopia. , 2011, American journal of ophthalmology.
[43] George A. Williams,et al. Photodynamic therapy of subfoveal choroidal neovascularization in pathologic myopia with verteporfin. 1-year results of a randomized clinical trial--VIP report no. 1. , 2001, Ophthalmology.